Breast Cancer
FDA Approves Oral SERD Elacestrant for ESR1-Mutant ER+, HER2– Metastatic Breast Cancer
January 27, 2023
Article
The FDA has granted an accelerated approval to elacestrant (Orserdu) for the treatment of patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer following at least 1 prior lines of endocrine therapy.
Patients With Breast Cancer and BRCA1, BRCA2, CHEK2, or PALB2 Germline Pathogenic Variants May Benefit From Enhanced Surveillance
January 25, 2023
Article
Patients with breast cancer who carry BRCA1, BRCA2, CHEK2, or PALB2 germline pathogenic variants may be at a greater risk for contralateral breast cancer and may benefit from enhanced surveillance and risk-reduction strategies.
Children Exposed to Maternal Cancer Show Normal Cognitive and Behavioral Outcomes
January 24, 2023
Article
An analysis of 141 children who had prenatal exposure to maternal cancer showed promising cognitive and behavioral functions at age 9 years.
Carroll Highlights Data Presented at SABCS from the CARRIERS and RIGHT Choice Studies
January 20, 2023
Article
Jamie Carroll, APRN, CNP, MSN, offers her perspective on emerging data from the 2022 San Antonio Breast Cancer Symposium.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16, 2023
Podcast
Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer
January 09, 2023
Article
Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, reflects on data presented at the San Antonio Breast Cancer Symposium.
Sacituzumab Govitecan Continues to Prolong Survival in Patients With HR+/HER2– Breast Cancer
January 08, 2023
Article
Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.
POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer
January 06, 2023
Article
Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.
CBD Oil Shows Modest Improvements in Tamoxifen-Related Adverse Effects
January 06, 2023
Article
Cannabidiol oil may be useful in helping patients with breast cancer manage tamoxifen-related adverse effects.
Antidiarrheal Prophylaxis Remains a Key Focus in TKI Treatment for Patients with HER2+ Breast Cancer
January 04, 2023
Article
Loperamide prophylaxis was linked to low rates of grade 3 diarrhea in patients receiving adjuvant pyrotinib, but better antidiarrheal prophylaxis options are still needed in this setting.